Amarin Corporation PLC Asset Resilience Ratio
Amarin Corporation PLC asset resilience ratio. Amarin Corporation PLC (AMRN) has an Asset Resilience Ratio of 27.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amarin Corporation PLC liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amarin Corporation PLC (2000–2025)
Asset resilience ratio of Amarin Corporation PLC from 2000 to 2025. This chart shows how Amarin Corporation PLC's Asset Resilience Ratio has changed over time. Read Amarin Corporation PLC total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Amarin Corporation PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AMRN current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $176.76 Million | 27.37% |
| Total Liquid Assets | $176.76 Million | 27.37% |
Asset Resilience Insights
- Very High Liquidity: Amarin Corporation PLC maintains exceptional liquid asset reserves at 27.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Amarin Corporation PLC Industry Peers by Asset Resilience Ratio
Compare Amarin Corporation PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Amarin Corporation PLC Asset Resilience Ratio by Year (2000–2025)
Amarin Corporation PLC asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Amarin Corporation PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.04% | $167.93 Million | $670.77 Million | -0.23pp |
| 2024-12-31 | 25.27% | $173.18 Million | $685.35 Million | +10.67pp |
| 2023-12-31 | 14.60% | $121.41 Million | $831.68 Million | +4.25pp |
| 2022-12-31 | 10.35% | $91.69 Million | $886.18 Million | -11.62pp |
| 2021-12-31 | 21.97% | $234.67 Million | $1.07 Billion | -10.53pp |
| 2020-12-31 | 32.50% | $313.97 Million | $966.02 Million | +32.13pp |
| 2017-12-31 | 0.37% | $600.00K | $161.60 Million | +0.01pp |
| 2016-12-31 | 0.36% | $600.00K | $167.00 Million | +0.01pp |
| 2015-12-31 | 0.35% | $600.00K | $173.46 Million | 0.00pp |
| 2014-12-31 | 0.35% | $600.00K | $171.11 Million | -0.05pp |
| 2013-12-31 | 0.40% | $1.00 Million | $252.48 Million | -7.79pp |
| 2008-12-31 | 8.18% | $3.00 Million | $36.66 Million | +8.11pp |
| 2001-12-31 | 0.07% | $64.00K | $90.99 Million | -30.90pp |
| 2000-12-31 | 30.97% | $15.05 Million | $48.60 Million | -- |
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more